Skip to content
Betaline

Texas Top Legal Officer Files Lawsuit Against Tylenol Producers Over Autism Spectrum Assertions

Courtroom Proceedings
Ken Paxton, a Trump ally campaigning for the United States Senate, alleged pharmaceutical manufacturers of hiding safety concerns of acetaminophen

Texas Attorney General Ken Paxton is taking legal action against the manufacturers of acetaminophen, alleging the firms hid potential risks that the pain reliever created to children's brain development.

The lawsuit comes four weeks after President Donald Trump promoted an unproven link between using acetaminophen - referred to as paracetamol - during pregnancy and autism in young ones.

The attorney general is taking legal action against Johnson & Johnson, which formerly manufactured the drug, the only pain reliever recommended for women during pregnancy, and Kenvue, which presently makes it.

In a declaration, he claimed they "betrayed America by gaining financially from suffering and pushing pills without regard for the risks."

The company states there is insufficient reliable data connecting Tylenol to autism spectrum disorder.

"These companies deceived for years, deliberately risking millions to boost earnings," Paxton, a Republican, declared.

Kenvue commented that it was "seriously troubled by the spread of false claims on the security of paracetamol and the potential impact that could have on the well-being of women and children in America."

On its official site, the company also said it had "regularly reviewed the applicable studies and there is lacking reliable evidence that demonstrates a verified association between taking paracetamol and autism spectrum disorder."

Groups acting on behalf of medical professionals and health professionals agree.

The American College of Obstetricians and Gynecologists has said paracetamol - the primary component in acetaminophen - is one of the few options for expectant mothers to address pain and elevated temperature, which can pose serious health risks if left untreated.

"In more than two decades of investigation on the consumption of paracetamol in pregnancy, not a single reputable study has successfully concluded that the usage of paracetamol in any period of gestation results in brain development issues in children," the group commented.

This legal action references latest statements from the Trump administration in asserting the drug is allegedly unsafe.

Recently, the former president caused concern from public health officials when he instructed pregnant women to "struggle intensely" not to consume Tylenol when sick.

The FDA then issued a notice that physicians should contemplate reducing the use of acetaminophen, while also declaring that "a direct connection" between the medication and autism in minors has remains unverified.

Health Secretary RFK Jr, who manages the FDA, had pledged in spring to initiate "comprehensive study program" that would establish the cause of autism spectrum disorder in a short period.

But authorities cautioned that identifying a single cause of autism spectrum disorder - considered by experts to be the outcome of a complicated interplay of genetic and surrounding conditions - would be difficult.

Autism is a form of enduring cognitive variation and disability that impacts how persons perceive and relate to the surroundings, and is diagnosed using medical professional evaluations.

In his lawsuit, Paxton - a Trump ally who is campaigning for the Senate - claims Kenvue and J&J "deliberately disregarded and sought to suppress the science" around paracetamol and autism.

The case aims to force the companies "eliminate any marketing or advertising" that claims acetaminophen is safe for expectant mothers.

The Texas lawsuit echoes the grievances of a group of guardians of minors with autism and ADHD who took legal action against the manufacturers of Tylenol in recently.

The court threw out the lawsuit, stating studies from the family's specialists was inconclusive.

About the author

Michael Miller

A tech journalist with over a decade of experience covering AI, cybersecurity, and emerging technologies across global markets.

Betaline

Type to search articles.